Rubius Therapeutics
620 Memorial Drive
Suite 100W
Cambridge
Massachusetts
02139
United States
Tel: 617-218-1606
Website: http://www.rubiustx.com/
25 articles with Rubius Therapeutics
-
Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018.
-
This year has been a strong one for biotech initial public offerings (IPO). According to the Wall Street Journal, as of mid-October, 55 biotech companies had raised $5.75 billion.
-
In the biotech hub area known as Pharm Country, the small state of Rhode Island often gets overlooked in favor of its larger neighbors, such as New York, New Jersey and Pennsylvania. But, the Ocean State is making some moves to enhance its image as a biotech hub, particularly in the wake of some ...
-
According to BioPharmCatalyst, there have been (or soon will be) 58 biopharma initial public offerings (IPOs) in 2018, and there’s still more than three months to go.
-
Once again, Amgen is accepting submissions for the 2018 Amgen-LabCentral Golden Ticket competition.
-
BeiGene, a biotech company based in Beijing, China and Cambridge, Massachusetts, announced it priced its initial public offering (IPO) on the Hong Kong stock exchange.
-
Rubius Therapeutics to Acquire Manufacturing Facility in Smithfield, Rhode Island to Produce Red Cell Therapeutics
7/25/2018
Rubius Therapeutics, Inc. (Nasdaq: RUBY), today announced that it has signed a purchase and sale agreement for the acquisition of a 135,000-square foot manufacturing facility located in Smithfield, Rhode Island.
-
So far in 2018, it’s been a good year for biotech initial public offerings (IPOs). According to a Crunchbase News article, in the second quarter of this year alone, there were at least 16 U.S. venture-backed biotech and healthcare IPOs—compared to only 11 tech IPOs in the same period.
-
Rubius Therapeutics, based in Cambridge, Massachusetts, has set the price of its initial public offering at $23 per share.
-
Manufacturing is the non-glamorous side of biopharma, although its impact on the economy shouldn’t be underestimated.
-
Three months after securing $100 million in a crossover financing round, Cambridge, Mass.-based Rubius Therapeutics is looking at a $200 million initial public offering to support its personalized red blood cell therapeutics program.
-
Biotech and pharmaceutical companies across the U.S. and globally shook up their senior leadership roles in the first week of June with new hires that included chief executive officers and directors.
-
Rubius Therapeutics Appoints Pablo J. Cagnoni, M.D. as Chief Executive Officer
6/6/2018
Torben Straight Nissen, Rubius’ President, will partner with Dr. Cagnoni to continue to advance the company’s pipeline and other business objectives.
-
There have been a number of leadership changes in biotech companies over the last week. BioSpace has put together a list of new c-suite level hires and position changes.
-
Despite raised awareness over the past few years, the gender diversity gap in the boardrooms of Fortune 1000 companies has remained at slightly less than 20 percent, as of 2017. There is evidence though that shows companies with more diversity at the highest levels see a higher return on investme...
-
Rubius Therapeutics Appoints Jonathan R. Symonds to Board of Directors
5/2/2018
Rubius Therapeutics, a biotechnology company pioneering the development of a versatile new class of ready-to-use cellular therapies, today announced the appointment of Jonathan R. Symonds, CBE, to its board of directors.
-
While the focus has been on M&A activity, Venture Capital firms have been investing billions in Biotech companies in 2018.
-
Rubius Therapeutics has closed on an oversubscribed $100 million crossover financing.
-
The fast-growing company will anchor 399 Binney St., an Alexandria Real Estate Equities property.
-
Rubius Therapeutics Appoints Francis Cuss and Catherine Sohn to Board of Directors
2/1/2018
Rubius Therapeutics today announced the appointments of Francis Cuss, MB, MChir, FRCP and Catherine Sohn, Pharm.D., to its board of directors.